Valproic acid-labeled chitosan nanoparticles promote recovery of neuronal injury after spinal cord injury
| Autor: | Zonglin Wang, Zhenlei Liu, Dimin Wang, Kai Wang, Hao Wu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Aging chitosan nanoparticles microglia Inflammation Pharmacology Neuroprotection Rats Sprague-Dawley NF160 medicine Animals Spinal cord injury Spinal Cord Injuries Chitosan Valproic Acid Microglia business.industry Recovery of Function Cell Biology Chitosan nanoparticles Tissue repair Spinal cord medicine.disease spinal cord injury Rats medicine.anatomical_structure Spinal Cord Nanoparticles medicine.symptom business Research Paper medicine.drug |
| Zdroj: | Aging (Albany NY) |
| ISSN: | 1945-4589 |
| DOI: | 10.18632/aging.103125 |
| Popis: | Chitosan nanoparticles have been recognized as a new type of biomaterials for treatment of spinal cord injury (SCI). To develop a novel treatment method targeted delivery injured spinal cord, valproic acid labeled chitosan nanoparticles (VA-CN) were constructed and evaluated in the treatment of SCI. Our results demonstrated that administration of VA-CN significantly promoted the recovery of the function and tissue repair after SCI. Moreover, we found treatment of VA-CN inhibited the reactive astrocytes after SCI. Furthermore, administration of VA-CN enhanced immunoreactions of neuronal related marker NF160, which suggested that VA-CN could promote the neuroprotective function in rats of SCI. The production of IL-1β, IL-6 and TNF-α were significantly decreased following treatment of VA-CN. Meanwhile, administration of VA-CN effectively improved the blood spinal cord barrier (BSCB) disruption after SCI. Administration of VA-CN could enhance the recovery of neuronal injury, suppress the reactive astrocytes and inflammation, and improve the blood spinal cord barrier disruption after SCI in rats. These results provided a novel and promising therapeutic manner for SCI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|